DUBLIN--(BUSINESS WIRE)--The "Global Endocrinology Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The Global Endocrinology Drugs Market to grow at a CAGR of 6.48% during the period 2018-2022.
Global Endocrinology Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of endocrinology drugs.
According to the report, one driver influencing this market is the increasing incidence of endocrine disorders. The increase in incidence of endocrine disorders may be due to the rising aging population globally. A trend that is generally seen in the incidence of endocrinology disorders such as diabetes is that the incidence is generally higher in low-and middle-income countries.
The use of biosimilars for endocrine disorders to be one of the major trends in the market A biosimilar is a biologic product that is approved based on demonstrating that it is similar to an approved biologic product, known as a reference product.
Further, the report states that one challenge affecting this market is the reimbursement challenges. Most endocrine disorders pose a significant economic burden on patients as well as on healthcare systems. Physicians and patients have concerns regarding inadequate reimbursement for most endocrine disorders, including diabetes.
Key vendors
- Abbvie
- Merck
- Novo Nordisk
- Pfizer
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: MARKET SEGMENTATION BY THERAPY AREA
- Comparison by therapy area
- Diabetes drugs
- Thyroid hormone disorder drugs
- hGH
- Testosterone replacement therapy
- Others
- Market opportunity by therapy area
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
- Association between obesity and endocrine disorders
- Use of biosimilars for endocrine disorders
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/research/2fp76n/global?w=4
